Nomi 2.5

Indications

Nomi is prescribed for the acute treatment of migraines in adults, whether with or without aura.

Pharmacology

Migraines are likely caused by local cranial vasodilatation or the release of sensory neuropeptides via nerve endings in the trigeminal system. Zolmitriptan’s therapeutic action in treating migraine headaches is attributed to its agonist effects on 5-HT1B/1D receptors, leading to constriction of cranial blood vessels and inhibition of pro-inflammatory neuropeptide release.

Dosage & Administration Tablet

The recommended initial dose of Zolmitriptan is a 2.5 mg tablet. The maximum single dose is 5 mg. If the migraine persists after 2 hours or returns after an initial improvement, a second dose may be taken at least 2 hours after the first. The maximum daily dose should not exceed 10 mg within a 24-hour period.

Nasal Spray

Administer one dose of Zolmitriptan Nasal Spray (5 mg) for acute migraine treatment. If the headache recurs, a second dose may be administered after 2 hours, not exceeding 10 mg in a 24-hour period. Clinical trials have shown effectiveness with a 5 mg dose administered into one nostril. Individual response to Zolmitriptan Nasal Spray may vary, and the choice of dose and administration route should be personalized. The efficacy of a second dose has not been conclusively established in placebo-controlled trials. Safety data beyond treating more than four headaches in a 30-day period is not established.

Contraindications

Nomi is contraindicated in patients with ischemic coronary artery disease, history of stroke, concurrent or recent use of a monoamine oxidase inhibitor, and known hypersensitivity to Zolmitriptan.

Side Effects

Common adverse reactions may include neck/throat/jaw pain or pressure, dizziness, tingling sensations, weakness, drowsiness, temperature sensations, nausea, heaviness sensation, and dry mouth.

Pregnancy & Lactation

Zolmitriptan is categorized as Pregnancy Category C. Its use during pregnancy should only occur if the potential benefits outweigh potential risks to the fetus. Whether Zolmitriptan is excreted in human milk is not known. Decisions regarding nursing should consider the drug’s importance to the mother.

Precautions & Warnings

Rare instances of serious cardiac adverse reactions, including acute myocardial infarction, have been reported shortly after administration. Sensations of tightness, pain, and pressure may occur in the chest, throat, neck, and jaw following treatment with Nomi.

Use in Special Populations

Nomi is not recommended for use in individuals under 18 years of age.

Therapeutic Class

5-HT Agonists

Storage Conditions

Store Nomi below 30°C, protecting it from light and moisture. Keep out of reach of children.